Lexaria Bioscience (LEXX) Q3 2024 earnings summary

Executive summary

• Revenue for the nine months ended May 31, 2024, increased to $380,278 from $195,467 year-over-year, driven by higher IP licensing fees, while B2B sales declined as focus shifted toward pharmaceuticals.

• Net loss narrowed to $3.6 million from $5.5 million year-over-year, reflecting reduced R&D expenses and lower general and administrative costs.

• Significant R&D progress included completion of a human pilot study for DehydraTECH-enhanced GLP-1 drugs and FDA clearance to proceed with a Phase 1b hypertension clinical trial.

• Multiple financings and warrant exercises raised over $10 million, strengthening liquidity and supporting ongoing R&D and operations.

Financial highlights

• Revenue: $380,278 for the nine months ended May 31, 2024, up 94% year-over-year.

• Net loss: $3,622,083 for the nine months ended May 31, 2024, compared to $5,463,510 in the prior year.

• Cash and cash equivalents: $8.5 million as of May 31, 2024, up from $1.4 million at August 31, 2023.

• Accumulated deficit: $49.4 million as of May 31, 2024.

• Weighted average shares outstanding: 11,274,845 for the nine months ended May 31, 2024.

Outlook and guidance

• Management expects continued significant operational expenses and net losses over the next 12 months as R&D activities expand.

• Current cash resources and anticipated licensing revenues are expected to cover financial obligations for at least the next twelve months.

• Ongoing and planned clinical studies in GLP-1 and CBD for hypertension are expected to drive future growth and potential commercial partnerships.